|
Report No. : |
343121 |
|
Report Date : |
28.09.2015 |
IDENTIFICATION DETAILS
|
Name : |
PHARMICELL CO., LTD. |
|
|
|
|
Registered Office : |
120, Dosan-daero, Gangnam-gu, Seoul |
|
|
|
|
Country : |
Korea (South) |
|
|
|
|
Financials (as on) : |
31.12.2014 |
|
|
|
|
Date of Incorporation : |
20.08.1968 |
|
|
|
|
Com. Reg. No.: |
314-81-00664 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Development of Stem Cell Therapeutics, Stem
Cell Banking, Bio-Based Business for Providing Technologies of Stem Cells,
Development of Cosmetics, Lab Devices |
|
|
|
|
No. of Employee : |
124 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Korea (South) |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
KOREA (SOUTH) ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated incredible economic growth and global integration to become a high-tech industrialized economy. In the 1960s, GDP per capita was comparable with levels in the poorer countries of Africa and Asia. In 2004, South Korea joined the trillion-dollar club of world economies. A system of close government and business ties, including directed credit and import restrictions, initially made this success possible. The government promoted the import of raw materials and technology at the expense of consumer goods, and encouraged savings and investment over consumption. The Asian FINANCIAL crisis of 1997-98 exposed longstanding weaknesses in South Korea's development model, including high debt/equity ratios and massive short-term foreign borrowing. GDP plunged by 7% in 1998, and then recovered by 9% in 1999-2000. South Korea adopted numerous economic reforms following the crisis, including greater openness to foreign investment and imports. Growth moderated to about 4% annually between 2003 and 2007. South Korea's export focused economy was hit hard by the 2008 global economic downturn, but quickly rebounded in subsequent years, reaching over 6% growth in 2010. The US-Korea Free TRADE Agreement was ratified by both governments in 2011 and went into effect in March 2012. Between 2012 and 2014, the economy experienced slow growth due to sluggish domestic consumption and investment. The administration in 2015 is likely to face the challenge of balancing heavy reliance on exports with developing domestic-oriented sectors, such as services. The South Korean economy's long-term challenges include a rapidly aging population, inflexible labor market, dominance of large conglomerates (chaebols), and the heavy reliance on exports, which comprise about half of GDP. In an effort to address the long term challenges and sustain economic growth, the current government has prioritized structural reforms, deregulation, promotion of entrepreneurship and creative industries, and the competitiveness of small and medium enterprises.
|
Source
: CIA |
Basic
|
Company Name |
PHARMICELL CO., LTD. |
|
Registered Address |
120, Dosan-daero,
Gangnam-gu, Seoul, Korea |
|
Building |
15FL., Chungho Bldg. |
|
Zip Code |
06038 |
|
Tel |
+82-2-3496-0114 |
|
Fax |
+82-2-3496-0149 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
15FL.,
Chungho Bldg.,120, Dosan-daero, Gangnam-gu, Seoul, Korea (Old Address
System : 15FL., Chungho Bldg., 3-2, Nonhyeon-dong, Gangnam-gu, Seoul, Korea) |
|
Tel |
+82-2-3496-0114 |
|
Fax |
+82-2-3496-0149 +82-2-3496-0159 |
|
Other Address |
20, Ilsan-ro, Wonju-si, Gangwon-do, Korea (Old Address
System : 162-33, Ilsan-dong, Wonju-si, Gangwon-do, Korea) |
|
Tel |
+82-33-745-4977 |
|
Fax |
+82-33-745-3066 |
|
Other Address |
484, Dunchon-daero, Jungwon-gu,
Seongnam-si, Gyeonggi-do, Korea (Old Address
System : 513-14, Sangdaewon-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea) |
|
Tel |
+82-31-777-9320 |
|
Fax |
+82-31-777-9326 |
|
Other Address |
8, Seokdang-gil, Onsan-eup, Ulju-gun,
Ulsan, Korea (Old Address
System : 857, Hwasan-ri, Onsan-eup, Ulju-gun, Ulsan, Korea) |
|
Tel |
|
|
Fax |
|
|
Type |
Export/Import |
|
Industry |
Manufacture of Other Chemical Materials and Chemical
Products |
|
Main
Business |
Development of Stem Cell Therapeutics, Stem
Cell Banking, Bio-Based Business for Providing Technologies of Stem Cells,
Development of Cosmetics, Lab Devices |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
08/20/1968 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Biochemicals(12352200) |
|
Sell |
Cosmetics(53131619) |
|
Sell |
Formulas and products for nutritional support(42231800) |
|
Sell |
Chemistry reagents or solutions(41116105) |
|
Sell |
Chemicals including Bio Chemicals and Gas Materials(12000000) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Medical science and research(85131700) |
|
Name |
Kim Hyun-Soo |
|
Address |
|
|
Date of Birth |
01/1964 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
27,950,406,000 |
||||||||||||||||||||||||
|
Employees |
124 |
||||||||||||||||||||||||
|
Formation |
Listed Company (Korea Stock Exchange : 005690) as of 05/20/1988 |
||||||||||||||||||||||||
|
Bank Details |
Shinhan Bank |
||||||||||||||||||||||||
|
Corporate Registered No. |
160111-0005177 |
||||||||||||||||||||||||
|
Business Registered No. |
314-81-00664 |
||||||||||||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 680231 |
||||||||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||||||||
|
Company History |
08/20/1968 Incorporated as YUHAW TRADE CO.,
LTD. 08/31/1987 Changed company name to YUHAW
CO., LTD. 08/21/2009 Changed company name to FCB
TWELVE CO., LTD., and moved to the present HQ address 09/15/2011
Acquired FCB PHARMICELL CO., LTD., and changed company name to the present name 03/31/2013 Acquired IDB CHEM CO., LTD. |
||||||||||||||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
President & CEO |
Mr. |
Kim Hyun-Soo |
Korean |
1964.01. |
Yonsei University, Korea |
|
President & CEO |
Mr. |
Kim Sung-Rae |
Korean |
1960.01. |
Sungkyunkwan University, Korea |
|
Director |
Mr. |
You Byung-Moo |
Korean |
1964.03. |
Hanyang University, Korea |
|
Outside Director |
Mr. |
Lee Kyung-Ho |
Korean |
1950.01. |
Seoul National University, Korea |
|
Auditor |
Mr. |
Kim Bok-Ki |
Korean |
1956.11. |
Myungji8 University, Korea |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
06/2015 |
10,816,926,628 |
100,740,474,716 |
-3,057,496,884 |
|
2014 |
20,155,408,356 |
98,844,665,046 |
-28,768,437,024 |
|
2013 |
33,405,394,268 |
99,368,848,822 |
-25,700,964,790 |
|
2012 |
10,885,749,776 |
130,760,805,121 |
-16,843,194,827 |
|
2011 |
9,663,140,452 |
100,904,653,488 |
-16,589,612,484 |
|
Authorized Capital(KRW) |
250,000,000,000 |
|
Paid-Up Capital(KRW) |
27,950,406,000 |
|
Total Issued Shares |
55,900,812 |
|
Unit : Korean Won |
01/01/2015~06/30/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Total
Assets |
100,740,474,716 |
98,844,665,046 |
99,368,848,822 |
|
Current Assets |
29,423,395,464 |
32,204,087,828 |
13,919,475,068 |
|
Cash
& Cash Equivalents |
18,065,128,281 |
22,175,631,518 |
1,631,329,537 |
|
Trade
Receivables & Other Receivables |
6,591,642,055 |
5,974,224,080 |
6,197,731,791 |
|
Other
Financial Assets |
375,000,000 |
350,047,950 |
880,216,740 |
|
Inventories |
3,134,267,656 |
2,588,109,571 |
4,613,684,321 |
|
Other
Current Assets |
1,234,997,472 |
1,102,242,299 |
531,110,789 |
|
Deferred
Income Tax Assets |
22,360,000 |
13,832,410 |
65,401,890 |
|
Non-Current Assets |
71,317,079,252 |
66,640,577,218 |
85,449,373,754 |
|
Marketable
Financial Instruments |
4,971,230,159 |
0 |
0 |
|
Other
Non-Current Financial Assets |
99,052,920 |
39,140,750 |
125,687,010 |
|
Investment_Real
Estates |
174,232,200 |
174,232,200 |
174,232,200 |
|
Tangibles |
4,368,322,526 |
4,512,229,078 |
5,729,348,100 |
|
Intangibles |
60,253,275,837 |
60,444,949,580 |
76,571,517,054 |
|
Other
Non-Current Assets |
1,450,965,610 |
1,470,025,610 |
2,848,589,390 |
|
Total Liabilities |
10,037,702,836 |
15,442,843,826 |
16,948,034,382 |
|
Current Liabilities |
5,648,047,115 |
11,261,445,158 |
12,831,307,486 |
|
Trade
Payables & Other Payables |
1,655,591,974 |
1,194,358,017 |
2,750,621,878 |
|
Short-Term
Borrowings |
0 |
1,500,000,000 |
2,000,000,000 |
|
Bonds with Warrants |
0 |
0 |
6,841,166,282 |
|
Convertible Bonds |
2,907,510,675 |
7,492,167,367 |
0 |
|
Other
Current Liabilities |
1,084,944,466 |
1,074,919,774 |
1,239,519,326 |
|
Non-Current Liabilities |
4,389,655,721 |
4,181,398,668 |
4,116,726,896 |
|
Confirmed
Salaries |
3,498,895,510 |
3,281,490,723 |
3,113,805,253 |
|
Other
Non-Current Liabilities |
890,760,211 |
899,907,945 |
1,002,921,643 |
|
Capital Stock |
27,950,406,000 |
26,329,346,000 |
21,702,660,000 |
|
Capital
Surplus |
172,684,840,096 |
164,267,137,195 |
139,411,691,111 |
|
Others |
-109,932,474,216 |
-107,194,661,975 |
-78,693,536,671 |
|
Total
Equity |
90,702,771,880 |
83,401,821,220 |
82,420,814,440 |
|
Liab.
& Shareholder’s Equity |
100,740,474,716 |
98,844,665,046 |
99,368,848,822 |
|
Unit : Korean Won |
01/01/2015~06/30/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Sales |
10,816,926,628 |
20,155,408,356 |
33,405,394,268 |
|
Cost of Sold Goods |
8,588,611,872 |
16,307,551,472 |
24,655,566,913 |
|
Gross Profit |
2,228,314,756 |
3,847,856,884 |
8,749,827,355 |
|
Selling & Admin. Expenses |
5,209,791,582 |
12,265,236,582 |
16,386,795,169 |
|
Operating Income |
-2,981,476,826 |
-8,417,379,698 |
-7,636,967,814 |
|
Other Operating Income |
186,013,697 |
816,133,330 |
1,909,999,329 |
|
Other Operating Expenses |
122,626,859 |
19,891,403,838 |
16,633,003,210 |
|
Finance Income |
158,375,400 |
252,165,319 |
470,975,781 |
|
Finance Expenses |
297,782,296 |
1,527,952,137 |
3,811,968,876 |
|
Income Before Taxes |
-3,057,496,884 |
-28,768,437,024 |
-25,700,964,790 |
|
Income Taxes Expenses |
0 |
0 |
0 |
|
Net Income |
-3,057,496,884 |
-28,768,437,024 |
-25,700,964,790 |
|
Unit : Korean Won |
01/01/2015~06/30/2015 |
As of 12/31/2014 |
As of 12/31/2013 |
|
Operating
Activities Cash Flows |
-1,769,955,056 |
-8,772,026,855 |
-2,687,726,821 |
|
Cash Flows from Operating |
-1,757,332,184 |
-8,442,035,844 |
-1,548,277,219 |
|
Net Income |
-3,057,496,884 |
-28,768,437,024 |
-25,700,964,790 |
|
Adjustment |
2,141,562,290 |
24,797,177,050 |
24,516,141,994 |
|
Changes in Asset/ & Liability |
-841,397,590 |
-4,470,775,870 |
-363,454,423 |
|
Interests Received |
145,593,210 |
170,124,282 |
474,903,371 |
|
Interests Paid |
-149,688,492 |
-551,684,773 |
-1,627,826,253 |
|
Income Taxes |
-8,527,590 |
51,569,480 |
13,473,280 |
|
Cash Flows from Investing |
-6,028,775,039 |
609,714,553 |
9,044,463,097 |
|
Cash Flows from Financing |
3,686,946,198 |
28,706,145,047 |
-15,738,594,538 |
|
Increase/Decrease in Cash |
-4,110,503,237 |
20,544,301,981 |
-9,381,858,262 |
|
Cash at the Beginning of Year |
22,175,631,518 |
1,631,329,537 |
11,013,187,799 |
|
Cash at the End of Year |
18,065,128,281 |
22,175,631,518 |
1,631,329,537 |
(*)The Subject needs
to be monitored because Operating Income is
(-)2,981,000,000
KRW and Income Before Taxes is (-)3,057,000,000 KRW
as of 06/30/2015, and it has been lasted for over 3 years.
|
Main Products & Services |
Development of Stem Cell Therapeutics, Stem
Cell Banking, Bio-Based Business for Providing Technologies of Stem Cells,
Development of Cosmetics, Lab Devices |
|
Detailed Products Spec. |
-- |
|
Technologies Acquired |
-- |
|
Suppliers |
-- |
|
Customers |
-- |
|
Competitors |
PHARMACHEM CO., LTD. 3RD FL., 309, JAMSILBON-DONG, SONGPA-GU,
SEOUL, KOREA TEL:+82-2-575-8914 FAX:+82-2-575-8913 DUKSAN PURE CHEMICALS CO., LTD. 608B-2L, BANWOL INDUSTRIAL COMPLEX, 635-1, SEONGGOK-DONG,
DANWON-GU, ANSAN-SI, GYEONGGI-DO, KOREA TEL:+82-31-495-4055 FAX:+82-31-495-4058 SECHANG INT`L CORP. A-1422, GALLERIA PALACE, 40, JAMSIL 3-DONG,
SONGPA-GU, SEOUL, KOREA TEL:+82-2-2145-4883 FAX:+82-2-2145-4893 |
|
Sales/ Unit :Thousand KRW |
06/2015 |
2014 |
2013 |
|
Export |
2,894,042 |
4,755,482 |
|
|
Domestic |
7,922,886 |
15,399,927 |
|
|
Total |
10,816,928 |
20,155,409 |
|
Not Available.
No.
----
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.66.10 |
|
|
1 |
Rs.100.89 |
|
Euro |
1 |
Rs.73.96 |
INFORMATION DETAILS
|
Analysis Done by
: |
TRI |
|
|
|
|
Report Prepared
by : |
ANK |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.